Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1428 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 4.2249 | 0.1734 | 0.1438 | 0.0192 | 0.8693 | 14.9521 | 0.96527 |
HCC1428 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7695 | 0.0143 | 0.0033 | 4.9999 | 3.7973 | 0.75865 |
HCC1428 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.012745 | -0.0145 | 0.4463 | 0.0566 | 1.2300 | 0.012006 | 0.9876 |
HCC1428 | Everolimus | mTOR1 | PI3K/mTOR | 0.031039 | 0.3462 | 0.5186 | 0.0192 | 0.1000 | 0.0006981 | 0.70927 |
HCC1428 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0059301 | -0.0001 | 0.6483 | 0.0519 | 1.1926 | 0.0053821 | 0.98873 |
HCC1428 | PF-4708671 | p70S6K | PI3K/mTOR | 69.2764 | 0.8643 | -0.0019 | -0.0001 | 0.8694 | 128.134 | 0.60897 |
HCC1428 | Buparlisib | pan PI3K | PI3K/mTOR | 0.69074 | -0.2646 | 0.3524 | 0.1087 | 1.9122 | 0.88637 | 0.99206 |
HCC1428 | Pictilisib | pan PI3K | PI3K/mTOR | 5.8689 | 0.1916 | 0.1171 | 0.0310 | 1.2411 | 14.2229 | 0.90007 |
HCC1428 | Ceritinib | ALK | RTK | 1.2414 | -0.8673 | 0.3014 | 0.1288 | 1.6178 | 2.4481 | 0.99584 |
HCC1428 | Neratinib | EGFR/HER2 | RTK | 1.4327 | -0.0412 | 0.1042 | 0.0283 | 1.5482 | 2.7752 | 0.9933 |
HCC1428 | Tivantinib | MET | RTK | 0.2516 | 0.0341 | 0.3664 | 0.1106 | 2.2041 | 0.23715 | 0.99573 |
HCC1428 | Cediranib | VEGFR/cKIT | RTK | 3.1657 | -0.5502 | 0.1943 | 0.0619 | 1.9637 | 5.5392 | 0.98192 |
HCC1428 | Cabozantinib | VEGFR2/MET | RTK | Inf | 0.6310 | 0.0204 | -0.0008 | 2.9241 | 4.2982 | 0.94377 |
HME1 | Abemaciclib | CDK4/6 | Cell cycle | 0.19935 | 0.0156 | 0.4285 | 0.0217 | 0.6437 | 0.22196 | 0.98583 |
HME1 | Palbociclib | CDK4/6 | Cell cycle | 0.22285 | 0.2572 | 0.2611 | 0.0111 | 0.9777 | 0.10881 | 0.98803 |
HME1 | AZD7762 | CHK1/2 | Cell cycle | 0.2501 | -0.4780 | 0.4638 | 0.2260 | 1.0093 | 0.48873 | 0.98439 |
HME1 | Volasertib | PLK | Cell cycle | 0.017242 | -0.0817 | 0.4263 | 0.1273 | 3.6204 | 0.017483 | 0.99425 |
HME1 | Dinaciclib | pan CDK | Cell cycle | 0.012053 | -0.2848 | 0.5701 | 0.2465 | 5.0000 | 0.013188 | 0.9972 |
HME1 | Cisplatin | Chemo | Chemotherapy | 1.1201 | -0.2180 | 0.2969 | 0.0782 | 0.8418 | 3.0767 | 0.99525 |
HME1 | Doxorubicin | Chemo | Chemotherapy | 0.0047147 | -0.3985 | 0.8359 | 0.2785 | 0.9521 | 0.0078037 | 0.96003 |
HME1 | Taxol | Chemo | Chemotherapy | 0.0031675 | -0.2241 | 0.6794 | 0.2401 | 1.5314 | 0.0037399 | 0.98563 |
HME1 | Topotecan | Topo I | Chemotherapy | 0.0072669 | -0.3399 | 0.8727 | 0.2534 | 1.2621 | 0.0091245 | 0.95352 |
HME1 | Etoposide | Topo II | Chemotherapy | 0.13797 | -0.3838 | 0.5421 | 0.1754 | 1.3297 | 0.19469 | 0.98888 |
HME1 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.18336 | -0.0749 | 0.4174 | 0.0505 | 1.1864 | 0.19403 | 0.97949 |
HME1 | Trametinib | MEK | MAPK/nRTK | 0.0057339 | 0.2032 | 0.4387 | 0.0257 | 2.4280 | 0.0044228 | 0.99436 |